Written by: Jeremiah Moore, PharmD, University of Rochester Medical Center

Download Here

This PQI will provide background on the novel medication selinexor for patients with multiple myeloma (MM) who have received at least one prior therapy, relapsed, refractory multiple myeloma (RR-MM), and relapsed, refractory diffuse large b-cell lymphoma (RR-DLBCL) and discuss effective practices to maximize the use of selinexor therapy.
Continue reading Selinexor (Xpovio®) Patient Management

Read More